These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 20516026)
1. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus. Yip J; Aghdassi E; Su J; Lou W; Reich H; Bargman J; Scholey J; Gladman DD; Urowitz MB; Fortin PR J Rheumatol; 2010 Aug; 37(8):1667-72. PubMed ID: 20516026 [TBL] [Abstract][Full Text] [Related]
2. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031 [TBL] [Abstract][Full Text] [Related]
3. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Mahmoud RA; El-Gendi HI; Ahmed HH Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275 [TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus. El-Banawy HS; Gaber EW; Maharem DA; Matrawy KA J Nephrol; 2012; 25(4):541-50. PubMed ID: 21956768 [TBL] [Abstract][Full Text] [Related]
5. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989 [TBL] [Abstract][Full Text] [Related]
6. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552 [TBL] [Abstract][Full Text] [Related]
7. The effect of menopause on disease activity in systemic lupus erythematosus. Urowitz MB; Ibañez D; Jerome D; Gladman DD J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295 [TBL] [Abstract][Full Text] [Related]
8. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Pradhan VD; Patwardhan MM; Ghosh K Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543 [TBL] [Abstract][Full Text] [Related]
9. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. Alzawawy A; Zohary M; Ablordiny M; Eldalie M Int J Rheum Dis; 2009 Dec; 12(4):311-8. PubMed ID: 20374368 [TBL] [Abstract][Full Text] [Related]
10. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629 [TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Mak A; Cheung BM; Mok CC; Leung R; Lau CS Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522 [TBL] [Abstract][Full Text] [Related]
12. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346 [TBL] [Abstract][Full Text] [Related]
13. Negative correlation between fetuin-A and indices of vascular disease in systemic lupus erythematosus patients with and without lupus nephritis. Abdel-Wahab AF; Fathy O; Al-Harizy R Arab J Nephrol Transplant; 2013 Jan; 6(1):11-20. PubMed ID: 23282228 [TBL] [Abstract][Full Text] [Related]
14. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. Ibañez D; Urowitz MB; Gladman DD J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus. Urquizu-Padilla M; Balada E; Cortés F; Pérez EH; Vilardell-Tarrés M; Ordi-Ros J J Rheumatol; 2009 May; 36(5):953-60. PubMed ID: 19332622 [TBL] [Abstract][Full Text] [Related]